Global STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030 – Promising Leads are Anticipated to be Launched Over the Coming Decade…

DUBLIN, Dec. 18, 2020 /PRNewswire/ -- The "STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The "STING Pathway Targeting Therapeutics and Technologies" report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. Basically, the STING pathway offers an alternative approach to harnessing the immune system, in order to pharmacologically treat a number of clinical conditions, including oncological and autoimmune disorders. The aforementioned therapeutic benefits can be achieved using modulators of the STING/cGAS-pathway. Over the years, a number of such modulators, capable of either activating or downregulating the STING pathway, have been developed. More than 50 experimental interventions based on this relatively novel concept are currently being developed for the treatment of oncological, autoimmune and inflammatory disorders.

The popularity of STING pathway modulation and growing interest of drug developers in this upcoming field of therapeutics is evident in the rising volume of affiliated scientific literature (1,000+ related articles on NCBI's PubMed portal since 2015). Moreover, capital investments worth over USD 2.6 billion have been made by various private and public sector investors to fund product development activity. In addition, there have been multiple, high value technology licensing deals in this domain, since 2015.

As a result, there has been a considerable rise in number of companies taking initiatives in this field, over the past 4-5 years alone. Interestingly, several big pharma players are also actively evaluating multiple STING agonists/antagonists. It is also worth noting that molecular research into the pathogenesis of the novel SARS-CoV-2 viral strain suggests that COVID-19 may be a STING-related disorder, characterized by delayed over-secretion of IFN-?.

STING, in humans, is mostly expressed in lung alveolar epithelial cells, endothelial cells, and spleen cells, which are considered crucial for COVID-19 pathogenesis. Therefore, rapid assessments of STING polymorphisms may actually be useful in identifying individuals who are at high risks of contracting a severe form of this infection. Further, a better understanding of the underlying mechanisms associated with the novel coronavirus induced STING-pathway over-activation, may enable the development of potential therapeutic candidates against COVID-19.

Currently, there are no approved STING pathway-targeting drugs/therapy products in the market. However, some promising leads are anticipated to be launched over the coming decade, following which the market is projected to grow at a substantial pace.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of STING pathway modulators. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030.

Key Topics Covered:

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Key Questions Answered1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Stimulator of Interferon Genes (STING) Pathway 3.2. STING Signaling 3.3. STING Pathway Modulators3.4. Key Variants of STING3.5. Non-immunological Functions of the STING Pathway3.6. Concluding Remarks

4. STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. STING Pathway Targeting Therapeutics: Development Pipeline4.3. STING Pathway Targeting Therapeutics: Developer Landscape4.4. STING Pathway Targeting Therapeutics: List of Clinical Trials

5. STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE5.1. Chapter Overview5.2. STING Pathway Targeting Technologies: List of Technology Developers

6. COMPANY PROFILES6.1. Chapter Overview6.2 STING Agonist Developers6.2.1. Aduro Biotech6.2.1.1. Company Overview6.2.1.2. Financial Information6.2.1.3. Product Description: ADU-S100 (MIW815)6.2.1.4. Recent Developments and Future Outlook6.2.2. Bristol-Myers Squibb6.2.3. Eisai6.2.4 GlaxoSmithKline6.2.5. ImmuneSensor Therapeutics6.2.6. Merck6.2.7. Noxopharm6.2.8. Spring Bank Pharmaceuticals6.2.9. Synlogic6.3. STING Antagonist Developers6.3.1 Avammune Therapeutics6.3.2. Curadev6.3.3 ImmuneSensor Therapeutics6.3.4. Nimbus Therapeutics6.3.5. Sirenas6.3.6. Spring Bank Pharmaceuticals6.3.7. STINGINN6.3.8. STipe Therapeutics

7. ACADEMIC GRANT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. STING Pathway Targeting Therapeutics: List of Academic Grants7.4. Grant Attractiveness Analysis

8. STING RELATED INITIATIVES OF BIG PHARMACEUTICALS PLAYERS8.1. Chapter Overview8.2. Scope and Methodology8.3. Initiatives Undertaken by Big Pharma Players8.4. Benchmarking Big Pharma Players

9. START-UP HEALTH INDEXING9.1. Chapter Overview9.2. Scope and Methodology9.3. Benchmarking of Start-ups

10. PUBLICATION ANALYSIS10.1. Chapter Overview10.2. Scope and Methodology10.3. STING Pathway Targeting Therapeutics: Recent Publications

11. PARTNERSHIPS AND COLLABORATIONS11.1. Chapter Overview11.2. Partnership Models11.3. STING Pathway Targeting Therapeutics: Recent Partnerships

12. FUNDING AND INVESTMENT ANALYSIS12.1. Chapter Overview12.2. Types of Funding12.3. STING Pathway Targeting Therapeutics: Recent Funding Instances12.4. Concluding Remarks

13. MARKET SIZING AND OPPORTUNITY ANALYSIS13.1. Chapter Overview13.2. Key Assumptions and Forecast Methodology

14. EXECUTIVE INSIGHTS

15. CONCLUDING REMARKS15.1. Chapter Overview15.2. Key Takeaways

16. APPENDIX 1: TABULATED DATA

For more information about this report visit https://www.researchandmarkets.com/r/by50j8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

More here:

Global STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030 - Promising Leads are Anticipated to be Launched Over the Coming Decade...